Advertisement
| first line therapy for multiple myeloma: Multiple Myeloma Morie A. Gertz, S. Vincent Rajkumar, 2013-10-01 This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment. |
| first line therapy for multiple myeloma: Allogeneic Stem Cell Transplantation Hillard M. Lazarus, Mary J. Laughlin, 2010-03-02 Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation. |
| first line therapy for multiple myeloma: Handbook of Multiple Myeloma Mohamad Mohty, Jean-Luc Harousseau, 2015-07-14 This handbook is an in-depth and comprehensive guide to the pathophysiology, diagnosis, staging, treatment and management of patients with multiple myeloma. The Handbook was commissioned to address an unmet need for a book of this kind in the myeloma field and to provide busy healthcare professionals with an informative and educational review of the current and emerging treatment recommendations for multiple myeloma. Myeloma is a type of bone marrow cancer arising from plasma cells and is the second most common form of bone marrow cancer, but represents just 1% of all cancers. The causes of myeloma are not fully understood but it is thought to be caused by an interaction of both genetic and environmental factors. This Handbook discusses these issues as well the latest developments in the field and will be an invaluable source of topical information for all healthcare professionals with an interest in multiple myeloma. |
| first line therapy for multiple myeloma: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| first line therapy for multiple myeloma: Proteasome Inhibitors in Cancer Therapy Julian Adams, 2004-05-25 A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (VelcadeTM) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma. |
| first line therapy for multiple myeloma: Update on Multiple Myeloma Khalid Ahmed Al-Anazi, 2019 This book is a comprehensive overview of the recent developments in the clinical and research fields of multiple myeloma. It is divided into three main sections that cover a wide range of topics, including: epidemiology and pathogenesis of the disease, genetic targets and pathways, resistance to novel therapies, angiogenesis and anti-angiogenesis, hematopoietic stem cell transplantation, role of radiology and radiotherapy in myeloma, infectious complications, and management of multiple myeloma in resource-poor countries. |
| first line therapy for multiple myeloma: Multiple Myeloma - A New Era of Treatment Strategies Klaus Podar, Kenneth C. Anderson, 2012-01-03 Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced |
| first line therapy for multiple myeloma: Multiple Myeloma and Other Plasma Cell Neoplasms Meletios A. Dimopoulos, Thierry Facon, Evangelos Terpos, 2018-02-16 This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. |
| first line therapy for multiple myeloma: Myeloma Bone Disease G. David Roodman, 2010-04-28 This book presents the forefront in the science and clinical management of myeloma bone disease. Coverage begins with sections on clinical presentation, imaging, and biochemical markers and goes on to discuss radiation, surgical, and medical therapies. |
| first line therapy for multiple myeloma: Multiple Myeloma and Related Disorders Henry A. Azar, Michael Potter, 1973 |
| first line therapy for multiple myeloma: Multiple Myeloma Thomas Moehler, Hartmut Goldschmidt, 2011-04-21 Multiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy, including in particular the approval of novel and first-in-class drugs such as thalidomide, bortezomib, and lenalidomide. This book, written by internationally acknowledged experts, covers a wide range of topics relating to multiple myeloma, including history, epidemiology, pathophysiology, clinical features, staging, and prognostic systems. The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable. Individualized therapy and the variety of supportive treatment options, as described in this volume, will help in achieving this goal, as well as in reducing adverse events and improving quality of life. |
| first line therapy for multiple myeloma: The European Blood and Marrow Transplantation Textbook for Nurses Michelle Kenyon, Aleksandra Babic, 2018-03-14 This book is open access under a CC BY 4.0 license. This textbook, endorsed by the European Society for Blood and Marrow Transplantation (EBMT), provides adult and paediatric nurses with a full and informative guide covering all aspects of transplant nursing, from basic principles to advanced concepts. It takes the reader on a journey through the history of transplant nursing, including essential and progressive elements to help nurses improve their knowledge and benefit the patient experience, as well as a comprehensive introduction to research and auditing methods. This new volume specifically intended for nurses, complements the ESH-EBMT reference title, a popular educational resource originally developed in 2003 for physicians to accompany an annual training course also serving as an educational tool in its own right. This title is designed to develop the knowledge of nurses in transplantation. It is the first book of its kind specifically targeted at nurses in this specialist field and acknowledges the valuable contribution that nursing makes in this area. This volume presents information that is essential for the education of nurses new to transplantation, while also offering a valuable resource for more experienced nurses who wish to update their knowledge. |
| first line therapy for multiple myeloma: Outline of Oncology Therapeutics Mark J. Ratain, Margaret Tempero, Consuelo Skosey, 2001 This new resource presents comprehensive guidance on the full range of drugs used to fight cancer, including chemotherapeutic agents as well as adjuvant and palliative medications. A section of the book also deals with drug delivery devices. 116 experienced oncology specialistsincluding both physicians and nursesprovide thorough, interdisciplinary coverage of the theoretical and practical aspects of cancer management to benefit the entire oncology team. Uses a concise, outline format to provide rapid access to essential drug information. Progresses from discussions of the various systemic and regional agents through supportive care and drug-disease interactions to vascular access devices and pumps and general considerations. Covers all classes of oncology drugs, detailing their clinical considerations, side effects, and toxicities. Incorporates nursing considerations throughout to facilitate the successful implementation of physicians' treatment plans. |
| first line therapy for multiple myeloma: Cutaneous T-Cell Lymphoma Herschel S. Zackheim, 2004-10-28 Cutaneous T-cell lymphoma (CTCL) is a general term for many lymphomas of the skin including mycosis Fungoides and Sezary syndrome. This book presents the state of the art in CTCL epidemiology, clinical features, pathology, immunochemistry, diagnostic molecular techniques, staging and prognosis, and treatment. Edited by one of the leading experts in |
| first line therapy for multiple myeloma: The Drug Development Paradigm in Oncology National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, National Cancer Policy Forum, 2018-02-12 Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop. |
| first line therapy for multiple myeloma: Post-Authorization Safety Studies of Medicinal Products Ayad K. Ali, Abraham G. Hartzema, 2018-06-27 Post-Authorization Safety Studies of Medicinal Products: The PASS Book bridges the gap in the literature by providing a complete look at post-authorization safety studies and important pharmacoepidemiology and pharmacovigilance aspects. It covers various types and limitations of active surveillance programs, including the use of large databases and disparate data sources for rapid signal detection, as well as novel and advanced design and analysis approaches for causal interference from observational data. This book serves as an important reference for pharmacovigilance scientists and pharmacoepidemiologists who are searching for the appropriate study design to answer safety research questions. Readers will be able to effectively and efficiently design and interpret findings from post-authorization safety studies with the goal of improving the benefit-risk balance of a drug in order to optimize patient safety. - Discusses all types of observational studies in post-marketing drug safety assessment, from spontaneous reporting systems, to pragmatic trials, with examples from real-world settings - Presents various types of post-authorization safety studies - Offers solutions to the common challenges in the design and conduct of these studies - Highlights active surveillance programs, including common data models for rapid signal detection of drug safety issues |
| first line therapy for multiple myeloma: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues World Health Organization, 2001 This is the third volume in the new World Health Organization series on histological and genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered. This was a collaborative project of the European Association for Haematolpathology and the Society for Haematopathology and others. The WHO classification is based on the principles defined in the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification. Over 50 pathologists from around the world were involved in the project and proponents of all major lymphoma and leukaemia classifications have agreed to accept the WHO as the standard classification of haematological malignancies. So this classification represents the first true world wide concensus of haematologic malignancies. Colour photographs, magnetic resonance and ultrasound images and CT scans are included. |
| first line therapy for multiple myeloma: FDA's Drug Review Process and the Package Label Tom Brody, 2017-12-01 FDA's Drug Review Process and the Package Label provides guidance to pharmaceutical companies for writing FDA-submissions, such as the NDA, BLA, Clinical Study Reports, and Investigator's Brochures. The book provides guidance to medical writers for drafting FDA-submissions in a way more likely to persuade FDA reviewers to grant approval of the drug. In detail, the book reproduces data on efficacy and safety from one hundred different FDA-submissions (NDAs, BLAs). The book reproduces comments and complaints from FDA reviewers regarding data that are fragmentary, ambiguous, or that detract from the drug's approvability, and the book reveals how sponsors overcame FDA's concerns and how sponsors succeeded in persuading FDA to grant approval of the drug. The book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely text and data from NDAs and BLAs, as published on FDA's website. The source material for writing this book included about 80,000 pages from FDA's Medical Reviews, FDA's Clinical Pharmacology Reviews, and FDA's Pharmacology Reviews, from one hundred different NDAs or BLAs for one hundred different drugs. Each chapter focuses on a different section of the package label, e.g., the Dosage and Administration section or the Drug Interactions section, and demonstrates how the sponsor's data supported that section of the package label. - Reveals strategies for winning FDA approval and for drafting the package label - Examples are from one hundred FDA-submissions (NDAs, BLAs) for one hundred different drugs, e.g., for oncology, metabolic diseases, autoimmune diseases, and neurological diseases - This book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely, the data from NDAs and BLAs as published on FDA's website at the time FDA grants approval to the drug |
| first line therapy for multiple myeloma: Measuring Health Ian McDowell, 2006-03-09 Worldwide economic constraints on health care systems have highlighted the importance of evidence-based medicine and evidence-based health policy. The resulting clinical trials and health services research studies require instruments to monitor the outcomes of care and the output of the health system. However, the over-abundance of competing measurement scales can make choosing a measure difficult at best. Measuring Health provides in-depth reviews of over 100 of the leading health measurement tools and serves as a guide for choosing among them.LNow in its third edition, this book provides a critical overview of the field of health measurement, with a technical introduction and discussion of the history and future directions for the field. This latest edition updates the information on each of the measures previously reviewed, and includes a complete new chapter on anxiety measurement to accompany the one on depression. It has also added new instruments to those previously reviewed in each of the chapters in the book.LChapters cover measurements of physical disability, social health, psychological well-being, anxiety, depression, mental status testing, pain, general health status and quality of life. Each chapter presents a tabular comparison of the quality of the instruments reviewed, followed by a detailed description of each method, covering its purpose and conceptual basis, its reliability and validity and, where possible, shows a copy of the actual scale. To ensure accuracy of the information, each review has been approved by the original author of each instrument or by an acknowledged expert. |
| first line therapy for multiple myeloma: Clinical Trials in Oncology, Third Edition Stephanie Green, Jacqueline Benedetti, Angela Smith, John Crowley, 2012-05-09 The third edition of the bestselling Clinical Trials in Oncology provides a concise, nontechnical, and thoroughly up-to-date review of methods and issues related to cancer clinical trials. The authors emphasize the importance of proper study design, analysis, and data management and identify the pitfalls inherent in these processes. In addition, the book has been restructured to have separate chapters and expanded discussions on general clinical trials issues, and issues specific to Phases I, II, and III. New sections cover innovations in Phase I designs, randomized Phase II designs, and overcoming the challenges of array data. Although this book focuses on cancer trials, the same issues and concepts are important in any clinical setting. As always, the authors use clear, lucid prose and a multitude of real-world examples to convey the principles of successful trials without the need for a strong statistics or mathematics background. Armed with Clinical Trials in Oncology, Third Edition, clinicians and statisticians can avoid the many hazards that can jeopardize the success of a trial. |
| first line therapy for multiple myeloma: Upper Tract Urothelial Carcinoma Shahrokh F. Shariat, Evanguelos Xylinas, 2014-09-13 Upper Tract Urothelial Carcinoma represents the first book of its kind to be dedicated solely to UTUC. It's aim is to improve understanding and eventually care of a disease that is greatly understudied and underappreciated, yet commonly dealt with by many medical and urologic oncologists. The volume features new data regarding genetic susceptibility, gene expression studies and causative factors; contemporary concepts and controversies regarding diagnosis and staging of UTUC; prediction tools and their value in treatment decisions within each disease stage and patient selection and treatment options such as endoscopic management, distal ureterectomy, radical nephroureterectomy and chemotherapy. Up-to-date information regarding boundaries of surgical resection, indication and extent of lymphadenectomy is covered as well as the role of perioperative/neoadjuvant chemotherapy in patients with high-risk UTUC. Upper Tract Urothelial Carcinoma will be of great value to all Urologists, Medical Oncologists and fellows in Urologic Oncology as well as upper level residents in training in Urology and Medical Oncology. |
| first line therapy for multiple myeloma: Essentials of Cardiac Anesthesia for Noncardiac Surgery E-Book Joel A. Kaplan, 2018-07-21 Patients with cardiac conditions routinely present for noncardiac surgeries, requiring special protocols for perioperative assessment and management by the anesthesiologist. Essentials of Cardiac Anesthesia for Noncardiac Surgery: A Companion to Kaplan's Cardiac Anesthesia provides current, easily accessible information in this complex area, ideal for general anesthesiologists and non-cardiac subspecialists. From preoperative assessment through postoperative care, this practical reference covers all perioperative approaches to today's patients with cardiac conditions. - Provides guidance on the anesthetic diagnosis and management of the full range of cardiac lesions, helping minimize adverse outcomes and reduce complications for patients with common, complex, or uncommon cardiac conditions. - Includes complete coverage of echocardiography and current monitoring techniques needed for thorough perioperative assessment – all from the anesthesiologist's perspective. - Discusses safe and effective perioperative anesthetic management of patients presenting with advanced levels of cardiac care such as drug-eluting stents, multiple antiplatelet drugs, ventricular assist devices, multiple drugs for end-stage heart failure, and implanted electrical devices that produce cardiac resynchronization therapy, as well as patients with complicated obstetric problems or other significant cardiovascular issues. - Features a concise, easy-to-navigate format and Key Points boxes in each chapter that help you find answers quickly. |
| first line therapy for multiple myeloma: Specialist Training in Oncology E-Book Thankamma V Ajithkumar, Helen Hatcher, 2011-10-28 This textbook of oncology is aimed at specialist registrars in the early phase of their training. The basic concepts of cancer practice is touched upon in undergraduate and junior postgraduate years, but new trainees frequently seek additional resources to boost their knowledge in the field of Oncology. This title offers a concise account of the multidisciplinary management of common cancers and cancer-related problems appropriate to doctors at the start of their careers in this specialty. The content of the book is based on latest available evidence and reflects the training guidelines. Readable and concise style, aimed at the beginner in this specialty. Well illustrated in colour with graphics, clinical photographs and radiographs. Section on research methodology. Approachable design in the ‘Specialist Training in...’ series style. |
| first line therapy for multiple myeloma: Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders Morie A. Gertz, Philip R. Greipp, 2003-11-24 This handbook provides up-to-date and comprehensive treatment of all plasma cell disorders, including both common and rare disorders. All disease aspects from pathogenesis to most recent therapy are covered. The text originates from the Mayo Clinic, the world's most experienced institution in plasma cell disorders. Comprehensive treatise on all plasma cell disorders from the gene level to treatment of emergencies Chapters are uniformly organized for easy data access All authors are important authorities in their field with extensive clinical experience |
| first line therapy for multiple myeloma: Ferri's Clinical Advisor 2020 E-Book Fred F. Ferri, 2019-06-01 Significantly updated with the latest developments in diagnosis and treatment recommendations, Ferri's Clinical Advisor 2020 features the popular 5 books in 1 format to organize vast amounts of information in a clinically relevant, user-friendly manner. This efficient, intuitive format provides quick access to answers on 1,000 common medical conditions, including diseases and disorders, differential diagnoses, and laboratory tests – all reviewed by experts in key clinical fields. Updated algorithms, along with hundreds of new figures, tables, and boxes, ensure that you stay current with today's medical practice. - Contains significant updates throughout, covering all aspects of current diagnosis and treatment. - Features 27 all-new topics including chronic traumatic encephalopathy, medical marijuana, acute respiratory failure, gallbladder carcinoma, shift work disorder, radial tunnel syndrome, fertility preservation in women, fallopian tube cancer, primary chest wall cancer, large-bowel obstruction, inguinal hernia, and bundle branch block, among others. - Includes a new appendix covering Physician Quality Reporting System (PQRS) Measures. - Provides current ICD-10 insurance billing codes to help expedite insurance reimbursements. - Patient Teaching Guides for many of the diseases and disorders are included, most available in both English and Spanish versions, which can be downloaded and printed for patients. |
| first line therapy for multiple myeloma: Studies in the Quality of Life Norman Dalkey, 1972 |
| first line therapy for multiple myeloma: Neoplastic Diseases of the Blood Peter H. Wiernik, 1985 |
| first line therapy for multiple myeloma: Total Marrow Irradiation Jeffrey Y. C. Wong, Susanta K. Hui, 2021-03-01 This book, written by a team of international experts, concisely reviews the rationale and clinical application of image-guided total marrow irradiation, a rapidly emerging area in radiation oncology and hematopoietic cell transplantation. The aim is to provide the practicing radiation oncologist, hematologist, medical physicist, and bone marrow transplant researcher with a fundamental understanding of key aspects and an appreciation of the increasing significance of total marrow irradiation as conditioning for bone marrow transplantation. Detailed attention is paid to the impacts of recent advances in radiation therapy technology, functional PET and MRI, and understanding of the response of bone marrow to radiation. Full consideration is also given to the ways in which technological advances in image-guided radiation therapy have created new opportunities to treat bone marrow transplant patients with limited transplant options due to advanced disease, age, or co-morbidities. Further topics covered include the ways in which cancer stem cells and the marrow microenvironment influence response to radiation therapy and the implementation of new-generation predictive radiobiologic factors in the clinic. |
| first line therapy for multiple myeloma: Serum Free Light Chain Analysis A. R. Bradwell, 2006 |
| first line therapy for multiple myeloma: Outcomes Assessment in Cancer Joseph Lipscomb, Carolyn C. Gotay, Claire Snyder, 2011-08-18 The U.S. National Cancer Institute established the Cancer Outcomes Measurement Working Group in 2001 to evaluate measurements of the important and diverse impacts of cancer on individuals and populations. The findings and recommendations of the working group's 35 internationally recognized members provide alternative approaches for comprehensively measuring the burden of cancer and the effectiveness of preventive and therapeutic interventions. |
| first line therapy for multiple myeloma: Williams Hematology, 10th Edition Kenneth Kaushansky, Marshall A. Lichtman, Josef T. Prchal, Marcel M. Levi, Linda J. Burns, 2021-01-14 The landmark text that has guided generations of hematologists and related practitioners―updated with the latest research findings and improved format and presentation Long revered for its comprehensiveness and extraordinary depth of detail, Williams Hematology provides essential coverage of the origins, pathophysiological mechanisms, and management of benign and malignant disorders of blood and marrow cells and coagulation proteins. The text contains a wealth of basic science and translational pathophysiology for optimal, lifelong learning. Experts in research and clinical hematology, the editors are known worldwide for their contributions to the field. This new edition contains everything that has made Williams Hematology the go-to resource for decades and has been updated with new chapters and critical new research into the molecular mechanisms responsible for hematological disorders and the impact on diagnosis and treatment. And the new format enables you to access each chapter via content modules covering key topics, with summaries, infographics, and cases―all linked to review questions for self-assessment. The full-color presentation integrates images of blood and tissue findings where they are cited in the text. NEW TO THIS EDITION: Updated and revised content reflecting the latest research and developments Convenient format that streamlines the learning process and improves retention Additional chapters added on: Immune Checkpoint Inhibitors Immune Cell Therapy: Chimeric Antigen Receptor T Cell Therapy Immune Cell Therapy Dendritic Cell and Natural Killer Cell Therapy The processes of cell death and survival Application of Big Data and Deep Learning in Hematology Williams Hematology Cases with multiple-choice questions including detailed explanations—perfect preparation for the boards Continuously updated online content with comprehensive drug therapy database and other resources |
| first line therapy for multiple myeloma: Journal of the National Cancer Institute , 2011 |
| first line therapy for multiple myeloma: Multiple Myeloma and Related Disorders Gosta Gahrton, Brian Durie, Diana Samson, 2004-04-30 During the past decade there has been an enormous increase in knowledge of multiple myeloma and related disorders, reflected in the publication of more than 5000 articles on the subject in scientific journals. Much of this has come about as new technologies have made it possible to refine studies on chromosomes and genes and to gain information abo |
| first line therapy for multiple myeloma: Multiple Myeloma: New Insights for the Healthcare Professional: 2013 Edition , 2013-07-22 Multiple Myeloma: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Diagnosis and Screening. The editors have built Multiple Myeloma: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Multiple Myeloma: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/. |
| first line therapy for multiple myeloma: Myeloma Therapy Sagar Lonial, 2009-01-01 Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology, chemotherapy-based approaches, immune -based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders provides a comprehensive collection and an excellent resource in this time of rapid change in clinical and preclinical disease knowledge. It is important to realize that these changes did not occur in a vacuum. Partnerships between academic institutions, the pharmaceutical industry, patient advocacy groups, the National Cancer Institute, community onco- gists, and ultimately our patients worked closely together to realize these advances, and to effect the radical changes in therapy we have witnessed over the past few years. This book would not have been possible without contri- tions from each of the gifted scientists and clinicians who worked tirelessly to prepare their individual chapters all the while maintaining commitment to the scientific and clinical mission of advancing care. |
| first line therapy for multiple myeloma: The Bethesda Handbook of Clinical Oncology Sayan Paul, 2020-09-01 The Bethesda handbook of clinical oncology has been thoroughly reviewed and Ed it Ed by a group of renowned oncologists from reputed government and private cancer institutes of India to make the contents relevant and useful for the students and practitioners of oncology of the Indian subcontinent and South Asia. Salient features: data and evidences from India and South Asia have been added. All the chapters have been edited and updated as per most recent availableevidences and guidelines. More emphasis has been given to the type of cancers more commonly seen in this part of the world such as head and neck cancer, cancer cervix, breast cancer, etc. Chapters of basics of Radiation oncology and medical oncology have been revised. Additional and relevant information on cancer surgery has been added in each br>Chapter a management Flowchart has been added at the end of each br>Chapter for easy understanding and ready reference in the clinic. |
| first line therapy for multiple myeloma: The Bethesda Handbook of Clinical Oncology Jame Abraham, James L. Gulley, Carmen J. Allegra, 2012-03-28 Written by clinicians from the National Cancer Institute and other leading institutions, this comprehensive, clear, concise oncology handbook is designed specifically for quick bedside consultation. It covers all malignancies and offers busy clinicians practical guidelines on daily patient management, including commonly used treatment regimens and chemotherapy dosing and schedules. The user-friendly format features tables, charts, bullet points, and algorithms. The thoroughly updated Third Edition places an increased emphasis on practical clinical information, and includes new chemotherapeutic agents, dosages, and treatment regimens and the latest clinical trials data. New chapters focus on basic genomics for practicing oncologists and basic principles of radiation. The succinct yet detailed presentation is ideal for board review as well as clinical reference. |
| first line therapy for multiple myeloma: Immunomodulating Drugs for the Treatment of Cancer Asher A.A. Chanan-Khan, 2012-03-29 Immunomodulating Drugs for the Treatment of Cancer provides a comprehensive resource for clinicians and researchers regarding immunomodulatory (IMiDs) drugs and their rapidly emerging role in cancer medicine. This new class of anticancer agents has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity. |
| first line therapy for multiple myeloma: Angiogenesis Inhibition Rüdiger Liersch, Wolfgang E. Berdel, Torsten Kessler, 2009-12-24 Angiogenesis is attracting increased scientific and clinical interest. The identification of novel mediators and targeting molecules has led to significant progress in our understanding of tumor angiogenesis and tumor vessel targeting. Important advances in cancer treatment have already emerged, and in the future, blood vessel targeting will play a significant role within individualized therapeutic strategies. This volume provides a general overview of the latest developments in angiogenesis inhibition in cancer. All aspects from the bench to the bedside are considered, with detailed attention both to basic research and to its translation into clinical practice. Individual chapters are devoted to the roles of angiopoietins, HIF-1a, chemokines, PDGF and VEGF, and vascular integrins. The latest results of clinical trials are presented, and various advanced targeting strategies are discussed. This book will be invaluable to all who wish to learn of the most recent advances in this exciting field. |
| first line therapy for multiple myeloma: Resistance to Targeted Therapies in Multiple Myeloma Silvia CW Ling, Steven Trieu, 2021-07-23 Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development. |
Optimal Pharmacotherapy for Transplant-Ineligible Multiple …
Multiple myeloma is an incurable plasma cell neoplasm, characterized by an uncontrolled growth of plasma cells in the bone marrow. The preferred first-line therapy for newly diagnosed multiple …
Clinical Practice Guideline MULTIPLE MYELOMA - Myeloma …
Multiple myeloma (MM) is a malignancy of plasma cells characterised by an abnormal serum and /or urine immunoglobulin or free immunoglobulin light chain as a result of clonal expansion of plasma …
A phase I open-label single-arm study of dual targeting BCMA …
GC012F BCMA/CD19 dual-targeting CAR-T cell therapy shows very encouraging anti-tumor activity in transplant-eligible, high risk, newly diagnosed multiple myeloma patients
Insightsfrom theCIMMA study
Front line treatment in newly diagnosed multiple myeloma (NDMM) transplantation eligible (TE) patients remain challenging due to its impact on patient’s outcomes.
First Line Therapy in Multiple Myeloma: VAD vs Bortezomib
This paper aims to assess the response to first line treatment of patients included in the study and their correlation with the negative prognostic factors in multiple myeloma: age over 60 years, …
Bortezomib and thalidomide for the first-line treatment of …
• At presentation first line treatment consisting of chemotherapy followed by high-dose therapy with stem cell transplant (HDTSCT) is considered the standard of care - for patients younger …
REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN …
Introduction: Elderly patients with multiple myeloma have shorter survival outcomes than younger patients. In this study, we aimed to compare the efficacy and toxicity profiles of conventional and …
Balancing the Efficacy and Tolerability of First-line Treatment in ...
the field of myeloma treatments. In newly diagnosed young MM patients (<65 years of age), the standard treatment is autologous stem cell transplantation (ASCT). For elderly (>65 years of age) …
First-Line Therapy in the Transplant Candidate Multiple …
With the dual purpose of treating a symptomatic dis- ease and obtaining a maximized depth of response autologous stem cell support (ASCT) is the backbone of young multiple myeloma …
Multiple Myeloma Patient Handbook - Myeloma Canada
Myeloma Canada’s Multiple Myeloma Patient Handbook has been designed specifically for people living with myeloma, their families and their caregivers. The goal of this Handbook is to educate …
Characteristics and Outcomes of Patients With …
Limited real-world data exist to guide second-line (2L) treatment strategies for multiple myeloma patients who become refractory to lenalidomide (Len) in first-line therapy. This Greek MM …
The high cost burden of third- to fifth-line treatments for …
Table 1 outlines Medicare and patient costs for common first- through fifth-line therapies for nontransplant eligible MM patients, with emphasis on the highest cost drug within the regimen …
Multiple myeloma: practice patterns across Europe
(48%); lenalidomide was the most commonly used first-line maintenance therapy (45%) and second- and third-line agent overall (60% and 52% of patients at those lines, respectively). …
Phase I Open-Label Single-Arm Study of BCMA/CD19Dual …
deep and durable responses in multiple myeloma (MM) patients § BCMA is universally expressed on malignant plasma cells1 § CD19 is expressed on both multiple myeloma cells and their …
CAR-T cell therapy - Myeloma Australia
CAR-T cell therapy is a completely new way to treat multiple myeloma. It is a type of treatment known as an immunotherapy. This means that the treatment works with your own immune system …
Guidelines for the management of Multiple Myeloma
%PDF-1.5 %µµµµ 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92 ...
Hematologists’ Preferences for First-line Therapy …
According to guidelines published by the Japanese Society of Hematology, for patients with monoclonal gammopathy of undetermined signi - cance or asymptomatic myeloma, watchful …
Current Standards for First-Line Therapy of Multiple Myeloma
Current standards of care for first-line treatment of multiple myeloma are evolving rapidly because of the introduction of regimens based on novel agents with unique mechanisms of action: the …
Real-World Treatment Patterns, Time to Next Treatment, and …
Recently approved therapies for relapsed/refractory multiple myeloma provide patients and providers with advanced options for care. Real-world evaluations of treatment patterns and …
The Advent of Novel Treatment Options for Multiple Myeloma: …
BCMA-targeted immunotherapy, such as CAR-T therapy and bispecific antibodies, has also emerged as a highly promising novel treatment in patients who have received at least three prior …
Optimal Pharmacotherapy f…
Multiple myeloma is an incurable plasma cell neoplasm, characterized by an uncontrolled growth of …
Clinical Practice Guideline MULTIP…
Multiple myeloma (MM) is a malignancy of plasma cells characterised by an abnormal serum and /or urine …
A phase I open-label single-arm study o…
GC012F BCMA/CD19 dual-targeting CAR-T cell therapy shows very encouraging anti-tumor activity in transplant …
Insightsfrom theCIMMA study
Front line treatment in newly diagnosed multiple myeloma (NDMM) transplantation eligible (TE) patients …
First Line Therapy in Multiple Myelo…
This paper aims to assess the response to first line treatment of patients included in the study and their correlation …
